Table 2.
Time | Group | |||
---|---|---|---|---|
Mean (SE) | Gabapentin (n = 10) Mean (SE) | Placebo ( n = 14) Mean (SE) | ||
CP Threshold (Seconds) | Trough Methadone | Baseline | 7.61 (1.23) | 14.23 (1.40) |
Week 5 | 9.90 (1.56) | 13.78 (1.71) | ||
Within-group difference in pain between Week 5 and baseline ** | 2.29 (1.58) | −0.45 (2.21) | ||
Peak Methadone | Baseline | 7.54 (1.54) | 15.82 (2.24) | |
Week 5 | 10.49 (1.86) | 12.33 (1.77) | ||
Within-group difference in pain between Week 5 and baseline * | 2.95 (2.41) | −3.49 (2.85) | ||
CP Tolerance (Seconds) | Trough Methadone | Baseline | 11.15 (1.04) | 20.72 (1.76) |
Week 5 | 14.19 (1.79) | 19.73 (2.42) | ||
Within-group difference in pain between Week 5 and baseline *** | 3.04 (2.07) | −0.99 (2.99) | ||
Peak Methadone | Baseline | 13.43 (3.02) | 21.90 (2.40) | |
Week 5 | 15.71 (1.90) | 19.63 (2.96) | ||
Within-group difference in pain between Week 5 and baseline * | −0.72 (3.57) | −2.27 (3.81) |
Significant group difference observed at
p = 0.04,
p = 0.02,
p = 0.01
levels of significance using two-sample independent t-tests to test that the change scores are the same between groups versus not.